Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing Geriatric Population
3.1.1.2 Increasing Prevalence of Targeted Diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with NSAIDs
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
Chapter 4 Regulatory & Political Forces
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.1.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
Chapter 5 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Disease indication, 2018 - 2030
5.1 Disease Indication Market Share Analysis, 2021 & 2030
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030
5.3.1 Arthritis
5.3.1.1 Arthritis market estimates and forecast, 2018 - 2030
5.3.2 Migraine
5.3.2.1 Migraine market estimates and forecast, 2018 - 2030
5.3.3 Ophthalmic Diseases
5.3.3.1 Ophthalmic diseases market estimates and forecast, 2018 - 2030
5.3.4 Others
5.3.4.1 Other market estimates and forecast, 2018 - 2030
Chapter 6 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Route of Administration, 2018 - 2030
6.1 Route of Administration Market Share Analysis, 2021 & 2030
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030
6.3.1 Oral
6.3.1.1 Oral market estimates and forecast, 2018 - 2030
6.3.2 Topical
6.3.2.1 Topical market estimates and forecast, 2018 - 2030
6.3.3 Others
6.3.3.1 Other market estimates and forecast, 2018 - 2030
Chapter 7 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Distribution Channel, 2018 - 2030
7.1 Distribution Channel Market Share Analysis, 2021 & 2030
7.2 Segment Dashboard
7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030
7.3.1 Hospital Pharmacy
7.3.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030
7.3.2 Retail Pharmacy
7.3.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030
7.3.3 Online Pharmacy
7.3.3.1 Online pharmacy market estimates and forecast, 2018 - 2030
Chapter 8 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Region, 2018 - 2030
8.1 Regional Market Share Analysis, 2021 & 2030
8.2 Regional Market Dashboard
8.3 North America
8.3.1 North America market estimates and forecast, 2018 - 2030
8.3.2 U.S.
8.3.2.1 U.S. market estimates and forecast, 2018 - 2030
8.4 Canada
8.4.1. Canada market estimates and forecast, 2018 - 2030
8.5 Europe
8.5.1 Europe market estimates and forecast, 2018 - 2030
8.5.2 Germany
8.5.2.1 Germany market estimates and forecast, 2018 - 2030
8.5.3 UK
8.5.3.1 UK market estimates and forecast, 2018 - 2030
8.5.4 Spain
8.5.4.1 Spain market estimates and forecast, 2018 - 2030
8.5.5 France
8.5.5.1 France market estimates and forecast, 2018 - 2030
8.5.6 Italy
8.5.6.1 Italy market estimates and forecast, 2018 - 2030
8.6 Asia Pacific
8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030
8.6.2 Japan
8.6.2.1 Japan market estimates and forecast, 2018 - 2030
8.6.3 China
8.6.3.1 China market estimates and forecast, 2018 - 2030
8.6.4 India
8.6.4.1 India market estimates and forecast, 2018 - 2030
8.6.5 South Korea
8.6.5.1 South Korea market estimates and forecast, 2018 - 2030
8.6.6 Australia
8.6.6.1 Australia market estimates and forecast, 2018 - 2030
8.7 Latin America
8.7.1 Latin America market estimates and forecast, 2018 - 2030
8.7.2 Brazil
8.7.2.1 Brazil market estimates and forecast, 2018 - 2030
8.7.3 Mexico
8.7.3.1 Mexico market estimates and forecast, 2018 - 2030
8.7.4 Argentina
8.7.4.1 Argentina market estimates and forecast, 2018 - 2030
8.8 Middle East & Africa
8.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030
8.8.2 South Africa
8.8.2.1 South Africa market estimates and forecast, 2018 - 2030
8.8.3 UAE
8.8.3.1 UAE market estimates and forecast, 2018 - 2030
8.8.4 Saudi Arabia
8.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030
Chapter 9 Competitive & Vendor Landscape
9.1 Participant Categorization
9.1.1 Innovators
9.1.2 Market Leaders
9.2 Strategy Mapping
9.2.1 Key Strategies Chosen by Players in this Market Include:
9.2.1.1 Launch of new products
9.2.1.2 Acquisition
9.2.1.3 Expansion
9.2.1.4 Agreements, collaborations, partnerships
9.2.1.5 Others (realignment, divestment, market penetration):
9.3 Strategic Framework
9.3.1 Key Company Market Share Analysis, 2021
9.4 Company Profiles
9.4.1 Pfizer Inc.
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 Bayer AG
9.4.2.1 Company overview
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 GSK plc
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 Dr. Reddy’s Laboratories Ltd
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product pipeline
9.4.4.4 Strategic initiatives
9.4.5 Viatris Inc
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product pipeline
9.4.5.4 Strategic initiatives
9.4.6 Teva Pharmaceutical Industries Ltd.
9.4.6.1 Company overview
9.4.6.2 Product benchmarking
9.4.6.3 Strategic initiatives
9.4.7 Johnson and Johnson Services, Inc.
9.4.7.1 Company overview
9.4.7.2 Financial performance
9.4.7.3 Product benchmarking
9.4.8 Merck & Co., Inc.
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives